Once again, Neogenomics, Inc. is using an acquisition to build up its cancer-testing business. In a deal that closed on Jan. 10, the lab company acquired the Oncology Division of Human Longevity, based in San Diego. Neogenomics said it paid $37 million for the division of Human Longevity that does next-generation sequencing services for pharmaceutical […]
NeoGenomics Spends $37M for Human Longevity’s Oncology Division
This acquisition shows NeoGenomics going strong into next-gen gene sequencing for cancer patients
- By Joseph Burns
- > From the Volume XXVII No. 2 - January 27, 2020 Issue
